Creatinine-lactate score predicts mortality in non-acetaminophen-induced acute liver failure in patients listed for liver transplantation

Table 1 Patients’ characteristics at prioritization according to outcome

Variables	LT group n = 69	Non-LT group n = 31	p value
Age: mean ± SD, y	34.5 ± 13.7	37.7 ± 16.8	0.5000
Sex women: n (%)	51 (73.9)	27 (87.1)	0.1937
Encephalopathy: n (%)
Grades I/II	10 (14.7)	10 (32.2)	0.0592
Grade III/IV	58 (85.3)	21 (67.8)
Etiology: n (%)
A or B or C virus	13 (18.8)	4 (12.9)	0.3368
DILI	21 (30.4)	11 (35.5)	0.6479
Autoimmune hepatitis	14 (20.3)	1 (3.2)*	0.0212
Indeterminate	17 (24.6)	14 (45.2)*	0.0358
Wilson’s disease	2 (2.9)	2 (6.5)	0.5858
Budd-Chiari syndrome	1 (1.5)	0	1.0000
Jaundice-encephalopathy interval: n (%)
≤ 7 days	18 (28.1)	4 (16.0)	0.1803
> 7 and ≤ 28 days	28 (43.8)	13 (52.0)	0.3204
> 28 days	18 (28.1)	8 (32.0)	0.7970
Waiting list time: median (min–max), days	1 (0–9)	2 (0–7)	0.5020
INR: mean ± SD	5.09 ± 2.77	6.47 ± 3.90	0.1600
AST: mean ± SD, U/L	578 ± 578	493 ± 779	0.0590
Bilirubin: mean ± SD, mg/dL	28.31 ± 10.06	29.34 ± 11.44	0.6690
Creatinine: mean ± SD, mg/dL	1.55 ± 1.54	2.59 ± 2.34*	0.0020
Lactate: mean ± SD, mg/dL	40.35 ± 29.28	78.43 ± 48.27*	< 0.0001
MELD	38.3 ± 8.0	44.1 ± 8.0*	0.0010
BiLE score	10.3 ± 4.1	15.8 ± 5.5*	< 0.0001
Creatinine-Lactate score	160.4 ± 94.8	296.1 ± 131.0*	< 0.0001

LT group, liver transplant group; Non-LT group, patients died before LT; DILI, drug induced live injury; MELD, model for end-stage liver disease; BiLE score, bilirubin lactate etiology score; *p < 0.05 compared to LT group

ISSN: 1471-230X